TheraCryf PLC (TCF)
Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
0.18p
Buy
0.22p
0.00p (+0.00%)
Prices updated at 19 Dec 2025, 16:24 GMT
| Prices minimum 15 mins delay
Prices in GBX
Evgen Pharma PLC is a clinical stage drug development company focused on cancer and neurological disease. Its pipeline is based on Sulforadex technology which includes synthetic and stabilized analogues of sulforaphane.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2024 | 2025 |
|---|---|---|
| 396,000 | - | |
| - | - | |
| -4m | -2m | |
| -898.99 | - | |
| -3m | -2m | |
| -4m | -2m | |
| Sales, General and administrative | 1m | 904,000 |
| Interest expenses | - | - |
| Provision for income taxes | -429,000 | -144,000 |
| Operating expenses | 4m | 2m |
| Income before taxes | -4m | -2m |
| Net income available to common shareholders | -3m | -2m |
| -0.009 | -0.0013 | |
| Net interest income | - | 5,000 |
| Advertising and promotion | - | - |
| Net investment income, net | -6,000 | -9,000 |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -0.009 | -0.0013 |
| Free cash flow per share | -0.0089 | -0.0042 |
| Book value/share | 0.0062 | 0.0028 |
| Debt equity ratio | - | - |
Balance sheet
Year | 2024 | 2025 |
|---|---|---|
| Current assets | 3m | 5m |
| Current liabilities | 723,000 | 2m |
| Total capital | 2m | 6m |
| Total debt | - | - |
| Total equity | 2m | 6m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 3m | 8m |
| Total liabilities | - | - |
| Cash and cash equivalents | 2m | 2m |
| Common stock | 275m | 2,130m |
Cash flow
Year | 2024 | 2025 |
|---|---|---|
| Cash at beginning of period | 5m | 2m |
| Cash dividends paid | - | - |
| -3m | -2m | |
| Investments (gains) losses | - | -2m |
| 2m | 2m | |
| Net income | - | - |
| -3m | -2m | |
| - | - |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
